WO2019238893A1 - Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1 - Google Patents

Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1 Download PDF

Info

Publication number
WO2019238893A1
WO2019238893A1 PCT/EP2019/065617 EP2019065617W WO2019238893A1 WO 2019238893 A1 WO2019238893 A1 WO 2019238893A1 EP 2019065617 W EP2019065617 W EP 2019065617W WO 2019238893 A1 WO2019238893 A1 WO 2019238893A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
chi
treatment
use according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2019/065617
Other languages
English (en)
French (fr)
Inventor
Patrick Blanco
Estibaliz LAZARO
Fanny SAUVESTRE
Aurélien MATUIZZI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Original Assignee
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Centre Hospitalier Universitaire de Bordeaux, Universite de Bordeaux filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US17/251,059 priority Critical patent/US20210115131A1/en
Priority to EP19732299.3A priority patent/EP3807313A1/en
Priority to JP2020569836A priority patent/JP2021527107A/ja
Priority to CN201980038401.7A priority patent/CN112236453A/zh
Publication of WO2019238893A1 publication Critical patent/WO2019238893A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • Treatments usually used in vasculo-placental or immunological pathologies are poorly codified due to the lack of knowledge of pathophysiology, and the evaluation of their efficacy, alone or in combinantion, remains uncertain in the literature due to a lack of power and a lack of randomization of the studies. There is therefore a need for a novel therapeutic protocol effective especially in the prevention or treatment of chronic histiocytic intervillositis (CHI) or associated symptoms.
  • CHI chronic histiocytic intervillositis
  • Figure 1 represents violin plot of differential expression levels of proteins involved in the inflammasome pathway (CASP1 , PYCARD, NOD2, NLRP3) of healthy placentas (control, CTRL) versus those with CHI (intervillitis, CHI) ( * : p ⁇ 0.05; ** :p ⁇ 0.01 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
PCT/EP2019/065617 2018-06-14 2019-06-13 Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1 Ceased WO2019238893A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/251,059 US20210115131A1 (en) 2018-06-14 2019-06-13 Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
EP19732299.3A EP3807313A1 (en) 2018-06-14 2019-06-13 Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1
JP2020569836A JP2021527107A (ja) 2018-06-14 2019-06-13 インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療
CN201980038401.7A CN112236453A (zh) 2018-06-14 2019-06-13 使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305729.8 2018-06-14
EP18305729 2018-06-14

Publications (1)

Publication Number Publication Date
WO2019238893A1 true WO2019238893A1 (en) 2019-12-19

Family

ID=62791692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/065617 Ceased WO2019238893A1 (en) 2018-06-14 2019-06-13 Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1

Country Status (5)

Country Link
US (1) US20210115131A1 (https=)
EP (1) EP3807313A1 (https=)
JP (1) JP2021527107A (https=)
CN (1) CN112236453A (https=)
WO (1) WO2019238893A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441786B2 (en) 2020-11-18 2025-10-14 Novartis Ag Bispecific antibodies for use in treatment of NLRC4-GOF inflammasomapathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00546B (me) * 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素－1受体拮抗剂治疗非典型性肺炎的用途
CA2780976C (en) * 2009-11-25 2020-03-31 Hologic, Inc. Detection of intraamniotic infection

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
A. MUEHLENBACHS ET AL: "Genome-Wide Expression Analysis of Placental Malaria Reveals Features of Lymphoid Neogenesis during Chronic Infection", THE JOURNAL OF IMMUNOLOGY, vol. 179, no. 1, 1 July 2007 (2007-07-01), US, pages 557 - 565, XP055521837, ISSN: 0022-1767, DOI: 10.4049/jimmunol.179.1.557 *
BOYD ET AL., HUM. PATHOL., vol. 31, no. 11, 2000, pages 1389 - 1396
D CARNOVALE ET AL: "Aspirin dose dependently inhibits the interleukin-1[beta]-stimulated increase in inducible nitric oxide synthase, nitric oxide, and prostaglandin E2 production in rat ovarian dispersates cultured in vitro", FERTILITY AND STERILITY., vol. 75, no. 4, 1 April 2001 (2001-04-01), USA, pages 778 - 784, XP055521849, ISSN: 0015-0282, DOI: 10.1016/S0015-0282(00)01784-2 *
DOSS ET AL., HUM. PATHOL., vol. 26, no. 11, 1995, pages 1245 - 1251
LABARREREMULLEN, AM. J. REPROD. IMMUNOL. MICROBIOL., vol. 15, no. 3, 1987, pages 85 - 91
LUKAS FREITAG ET AL: "Expression analysis of leukocytes attracting cytokines in chronic histiocytic intervillositis of the placenta", INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 1 January 2013 (2013-01-01), United States, pages 1103 - 1111, XP055521840, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657363/pdf/ijcep0006-1103.pdf> [retrieved on 20181107] *
M LIGUMSKY ET AL: "Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.", GUT, vol. 31, no. 6, 1 June 1990 (1990-06-01), UK, pages 686 - 689, XP055521846, ISSN: 0017-5749, DOI: 10.1136/gut.31.6.686 *
MARCHAUDON ET AL., PLACENTA, vol. 32, no. 2, 2011, pages 140 - 145
MEKINIAN ET AL., AUTOIMMUNITY, vol. 48, no. 1, 2015, pages 40 - 45
NOBUAKI OZAWA ET AL: "Chronic histiocytic intervillositis in three consecutive pregnancies in a single patient: Differing clinical results and pathology according to treatment used : Recurrent chronic intervillositis", JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, vol. 43, no. 9, 1 September 2017 (2017-09-01), JP, pages 1504 - 1508, XP055521803, ISSN: 1341-8076, DOI: 10.1111/jog.13404 *
P GREALLY ET AL: "Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone", ARCHIVES OF DISEASE IN CHILDHOOD, 1 July 1994 (1994-07-01), England, pages 35 - 39, XP055521844, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1029909/pdf/archdisch00567-0042.pdf> [retrieved on 20181107], DOI: 10.1136/adc.71.1.35 *
ROTA ET AL., J. GYNECOL. OBSTET. BIOL. REPROD., vol. 35, no. 7, 2006, pages 711 - 719
See also references of EP3807313A1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441786B2 (en) 2020-11-18 2025-10-14 Novartis Ag Bispecific antibodies for use in treatment of NLRC4-GOF inflammasomapathy

Also Published As

Publication number Publication date
CN112236453A (zh) 2021-01-15
JP2021527107A (ja) 2021-10-11
EP3807313A1 (en) 2021-04-21
US20210115131A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
Pilette et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease
Tang et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy
Vignola et al. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis
Liang et al. Inhibition of IL-18 reduces renal fibrosis after ischemia-reperfusion
Li et al. Arctigenin suppresses renal interstitial fibrosis in a rat model of obstructive nephropathy
Zhang et al. Cadmium-induced immune abnormality is a key pathogenic event in human and rat models of preeclampsia
Palmer et al. Bentamapimod (JNK inhibitor AS602801) induces regression of endometriotic lesions in animal models
Baba et al. Distribution, subtype population, and IgE positivity of mast cells in chronic rhinosinusitis with nasal polyps
AU2006272913A1 (en) Methods of detecting and treating acute kidney injury
Yagi et al. Ibudilast inhibits cerebral aneurysms by down-regulating inflammation-related molecules in the vascular wall of rats
Zhu et al. Deletion of macrophage migration inhibitory factor ameliorates inflammation in mice model severe acute pancreatitis
Zheng et al. C5a/C5aR1 mediates IMQ‐induced psoriasiform skin inflammation by promoting IL‐17A production from γδ‐T cells
KR20150131260A (ko) 결장직장암의 치료 방법
Xiao et al. Losartan and Dexamethasone may inhibit chemotaxis to reduce the infiltration of Th22 cells in IgA nephropathy
Luna et al. Sildenafil (Viagra®) blocks inflammatory injury in LPS-induced mouse abortion: a potential prophylactic treatment against acute pregnancy loss?
US10639346B2 (en) Treating hyperammonemia, reducing plasma ammonia with TLR4 antagonists
Dejban et al. Inflammatory cells in nephrectomy tissue from patients without and with a history of urinary stone disease
Zeng et al. The protective effect of amitriptyline on experimental colitis through inhibiting TLR-4/MD-2 signaling pathway
US20210115131A1 (en) Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
Han et al. The intervention effect of nicotine on cervical fibroblast-myofibroblast differentiation in lipopolysaccharide-induced preterm birth model through activating the TGF-β1/Smad3 pathway
Rossi et al. Nlrp2 deletion ameliorates kidney damage in a mouse model of cystinosis
Alexopoulos et al. Relationship between interstitial infiltrates and steroid responsiveness of proteinuria in membranous nephropathy
Donker et al. Absence of in vivo generalized pro-inflammatory endothelial activation in severe, early-onset preeclampsia
Sharma et al. HDAC5 RNA interference ameliorates acute renal injury by upregulating KLF2 and inhibiting NALP3 expression in a mouse model of oxalate nephropathy
CN117106892A (zh) Txnrd1蛋白或其编码基因为靶点在银屑病预防和治疗中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19732299

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020569836

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019732299

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2019732299

Country of ref document: EP

Effective date: 20210114

WWW Wipo information: withdrawn in national office

Ref document number: 2019732299

Country of ref document: EP